Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections

Journal of Pharmaceutical Sciences

Volumn 100, Issue 12, 2011, Pages 5197-5205

  Matinkhoo, Sadaf ^a   Lynch, Karlene H ^a   Dennis, Jonathan J ^a   Finlay, Warren H ^a   Vehring, Reinhard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Aerosols; Biomaterials; Formulation; Microparticles; Processing; Pulmonary drug delivery; Spray drying

Indexed keywords

CASEIN; GELATIN; LEUCINE; POLOXAMER; PROBIOTIC AGENT; SURFACTANT; TREHALOSE; TYLOXAPOL;

AEROSOL; ARTICLE; BACTERIOPHAGE; DISPERSION; DRUG DOSAGE FORM; DRUG FORMULATION; DRY POWDER; LOW TEMPERATURE; LUNG; LUNG INFECTION; PARTICLE SIZE; POWDER INHALER; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING;

EID: 80054935550     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22715     Document Type: Article

References (58)

1. Govan J, Deretic V. 1996. Microbial pathogenesis in cystic fibrosis: Mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Mol Biol Rev 60:539-574.
2. Mahenthiralingam E, Urban TA, Goldberg JB. 2005. The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol 3:144-156.
3. Mandsberg LF, Ciofu O, Kirkby N, Christiansen LE, Poulsen H, Hoiby N. 2009. Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. Antimicrob Agents Chemother 53:2483-2491.
4. Seed KD, Dennis JJ. 2005. Isolation and characterization of bacteriophages of the Burkholderia cepacia complex. FEMS Microbiol Letters 251:273-280.
5. Valenza G, Tappe D, Turnwald D, Frosch M, König C, Hebestreit H, Abele-Horn M. 2008. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cystic Fibrosis 7:123-127.
6. Reinert R. 2009. The antimicrobial resistance profile of Streptococcus pneumoniae. Clinical Microbiol Infect 15:7-11.
7. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. 2009. Characterization of a New Metallo-{beta}-lactamase gene, blaNDM- 1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53:5046-5054.
8. Karthikeyan K, Thirunarayan M, Krishnan P. 2010. Coexistence of blaOXA-23 with blaNDM-1 and armA in clinical isolates of Acinetobacter baumannii from India. J Antimicrob Chemother 65:2253-2254.
9. WHO. 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. ISBN 978 924 159 9191.
10. Jassal M, Bishai WR. 2009. Extensively drug-resistant tuberculosis. Lancet Infect Dis 9:19-30.
11. Abedon ST, Thomas-Abedon C. 2010. Phage therapy pharmacology. Curr Pharm Biotechnol 11:28-47.
12. Broxmeyer L. 2004. Bacteriophages: Antibacterials with a future?. Med Hypotheses 62:889-893.
13. Kutateladze M, Adamia R. 2010. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol 28:591-595.
14. Monk A, Rees C, Barrow P, Hagens S, Harper D. 2010. Under the microscope: Bacteriophage applications: Where are we now?. Lett Appl Microbiol 51:363-369.
15. Parisien A, Allain B, Zhang J, Mandeville R, Lan C. 2008. Novel alternatives to antibiotics: Bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J Appl Microbiol 104:1-13.
16. Morgan AD, Bonsall MB, Buckling A. 2010. Impact of bacterial mutation rate on coevolutionary dynamics between bacteria and phages. Evolution 64:2980-2987.
17. Merabishvili M, Pirnay JP, Verbeken, G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L. 2009. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE 4:1-10.
18. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L, Aziz R. 2011. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: First steps towards treatment and prevention. PLoS ONE 6:e16963.
19. Golshahi L, Seed K, Dennis J, Finlay W. 2008. Toward modern inhalational bacteriophage therapy: Nebulization of bacteriophages of Burkholderia cepacia complex. J Aerosol Med Pulm Drug Deliv 21:351-360.
20. Sou T, Meeusen EN, de Veer M, Morton DAV, Kaminskas LM, McIntosh MP. 2011. New developments in dry powder pulmonary vaccine delivery. Trends Biotechnol 29:191-198.
21. Ackermann HW, Tremblay D, Moineau S. 2004. Long-term bacteriophage preservation. World Fed Cult Collections Newsl 38:35-40.
22. Golshahi L, Lynch K, Dennis J, Finlay W. 2010. In vitro lung delivery of bacteriophages KS4 M and ΦKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J Appl Microbiol 110:106-117.
23. Broadhead J, Edmond Rouan SK, Rhodes CT. 1992. The spray drying of pharmaceuticals. Drug Dev Ind Pharm 18:1169-1206.
24. Weers JG, Tarara TE, Clark AR. 2007. Design of fine particles for pulmonary drug delivery. Expert Opin Drug Deliv 4:297-313.
25. Vehring R. 2008. Pharmaceutical particle engineering via spray drying. Pharm Res 25:999-1022.
26. Muller-Merbach M, Rauscher T, Hinrichs J. 2005. Inactivation of bacteriophages by thermal and high-pressure treatment. Int Dairy J 15:777-784.
27. Skurnik M, Pajunen M, Kiljunen S. 2007. Biotechnological challenges of phage therapy. Biotechnol Lett 29:995-1003.
28. Chopin MC. 1980. Resistance of 17 mesophilic lactic Streptococcus bacteriophages to pasteurization and spray-drying. J Dairy Res 47:131-139.
29. Seed KD, Dennis JJ. 2009. Experimental bacteriophage therapy increases survival of Galleria mellonella larvae infected with clinically relevant strains of the Burkholderia cepacia complex. Antimicrob Agents Chemother 53:2005-2008.
30. Lynch K, Stothard P, Dennis J. 2010. Genomic analysis and relatedness of P2-like phages of the Burkholderia cepacia complex. BMC Genomics 11:599.
31. Fokine A, Battisti A, Bowman V, Efimov A, Kurochkina L, Chipman P, Mesyanzhinov V, Rossmann M. 2007. Cryo-EM study of the Pseudomonas bacteriophage [phi] KZ. Structure 15:1099-1104.
32. Mesyanzhinov V, Robben J, Grymonprez B, Kostyuchenko V, Bourkaltseva M, Sykilinda N, Krylov V, Volckaert G. 2002. The genome of bacteriophage [phi] KZ of Pseudomonas aeruginosa. J Mol Biol 317:1-19.
33. Holloway B, Cooper G. 1962. Lysogenic conversion in Pseudomonas aeruginosa. J Bacteriol 84:1321-1324.
34. Holloway B, Egan J, Monk M. 1960. Lysogeny in Pseudomonas aeruginosa. Aust J Exp Biol Med Sci 38:321-329.
35. Ameri M, Maa Y-F. 2006. Spray drying of biopharmaceuticals: Stability and process considerations. Drying Technol 24:763-768.
36. Sastry GM, Agmon N. 1997. Trehalose prevents myoglobin collapse and preserves its internal mobility. Biochem 36:7097-7108.
37. Satpathy GR, Török Z, Bali R, Dwyre DM, Little E, Walker NJ, Tablin F, Crowe JH, Tsvetkova, NM. 2004. Loading red blood cells with trehalose: A step towards biostabilization. Cryobiology 49:123-136.
38. Tarara TE, Stevenson CL, Thompson S, Vehring R, Sadrzadeh N. 2007. Methionine-containing protein or peptide compositions and methods of making and using. International Patent Application WO 2007/095288 A2.
39. Müller-Merbach M, Neve H, Hinrichs J. 2005. Kinetics of the thermal inactivation of the Lactococcus lactis bacteriophage P008. J Dairy Res 72:281-286.
40. Quiberoni A, Guglielmotti DM, Reinheimer JA. 2003. Inactivation of Lactobacillus delbrueckii bacteriophages by heat and biocides. Int J Food Microbiol 84:51-62.
41. Wong Y-L, Sampson S, Germishuizen WA, Goonesekera S, Caponetti G, Sadoff J, Bloom BR, Edwards D. 2007. Drying a tuberculosis vaccine without freezing. Proc Natl Acad Sci U S A 104:2591-2595.
42. Garcia-Contreras L, Fiegel J, Telko MJ, Elbert K, Hawi A, Thomas M, VerBerkmoes J, Germishuizen WA, Fourie PB, Hickey AJ, Edwards D. 2007. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother 51:2830-2836.
43. Learoyd T, Burrows J, French E, Seville P. 2009. Sustained delivery by leucine-modified chitosan spray-dried respirable powders. Int J Pharm 372:97-104.
44. Raula J, Thielmann F, Naderi M, Lehto V, Kauppinen E. 2010. Investigations on particle surface characteristics vs. dispersion behaviour of l-leucine coated carrier-free inhalable powders. Int J Pharm 385:79-85.
45. Feng A, Boraey M, Gwin M, Finlay P, Kuehl P, Vehring R. 2011. Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug delivery. Int J Pharm 409:156-163.
46. Li X, Anton N, Arpagaus C, Belleteix F, Vandamme T. 2010. Nanoparticles by spray drying using innovative new technology: The Büchi nano spray dryer b-90. J Controlled Release 147:304-310.
47. Schmid K, Arpagaus C, Friess W. 2011. Evaluation of the nano spray dryer B-90 for pharmaceutical applications. Pharm Dev Technol 16:287-294.
48. Stapleton K, Guentsch E, Hoskinson M, Finlay W. 2000. On the suitability of k-turbulence modeling for aerosol deposition in the mouth and throat: A comparison with experiment. J Aerosol Sci 31:739-749.
49. Grgic B, Finlay W, Burnell P, Heenan A. 2004. In vitro intersubject and intrasubject deposition measurements in realistic mouth-throat geometries. J Aerosol Sci 35:1025-1040.
50. Khanmohammadi M, Moeini M, Bagheri Garamarudi A, Sotudehnia A, Zarrabi M. 2009. Simultaneous determination of sucrose and trehalose in olive leaves by spectrophotometry utilizing partial least squares method. Acta Physiologiae Plantarum 31:865-869.
51. Nichols S, Brown D, Smurthwaite M. 1998. New concept for the variable flow rate Andersen cascade impactor and calibration data. J Aerosol Med 11:133-138.
52. Chew NYK, Tang P, Chan H-K, Raper JA. 2005. How much particle surface corrugation is sufficient to improve aerosol performance of powders?. Pharm Res 22:148-152.
53. Assi K, Chrystyn H. 2000. The device resistance of recently introduced dry-powder inhalers. J Pharm Pharmacol 52:58-58.
54. Bronsky EA, Grossman J, Henis MJ, Gallo PP, Yegen Ü, Cioppa GD, Kottakis J, Mehra S. 2004. Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults. Curr Med Res Opin 20:131-137.
55. Newman S, Busse W. 2002. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 96:293-304.
56. Ivey J, Vehring R. 2010. The use of modeling in spray drying of emulsions and suspensions accelerates formulation and process development. Comput Chem Eng 34:1030-1035.
57. Finlay WH. 2001. The mechanics of inhaled pharmaceutical aerosols. San Diego: Academic Press.
58. Wright A, Hawkins C, Änggård E, Harper D. 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic resistant Pseudomonas aeruginosa: A preliminary report of efficacy. Clin Otolaryngol 34:349-357.